Trial Search Results

Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study

The purpose of this study is to provide Defibrotide to patients diagnosed with VOD. Defibrotide is no longer available though the Emergency Use IND mechanism (also known as compassionate use, or single patient named use). This protocol is the only mechanism by which Defibrotide can be made available to patients in the U.S.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Jazz Pharmaceuticals


  • Drug: Defibrotide
  • Drug: Defibrotide


Phase 3


Inclusion Criteria:

Entry criteria include the following:

   1. Clinical diagnosis of VOD, made by Baltimore Criteria, Modified Seattle Criteria, or
   biopsy proven:

   1.1 Baltimore Criteria- Bilirubin ≥2 mg/dL and at least 2 of the following clinical

      - Ascites (radiographic or physical exam)

      - Weight gain of ≥5% compared to the day of conditioning-- if this value is not
      available, the weight on the date of admission to the SCT unit may be used)

      - Hepatomegaly; increased over baseline.

   1.2 Modified Seattle Criteria: At least two of the following

      - Bilirubin ≥2 mg/dL

      - Ascites (radiographic or physical exam) and/or weight gain ≥5% above baseline
      weight (defined as weight on the first day of conditioning- if this value is not
      available, the weight on the date of admission to the SCT unit may be used)

      - hepatomegaly increased over baseline

   1.3 Patients that do not meet the Baltimore Criteria or Modified Seattle Criteria and
   have biopsy proven VOD are eligible.

   2. Patient must also provide written informed consent.

Exclusion Criteria:

   - Use of any medication which increases the risk of hemorrhage is disallowed. Use of
   heparin or other anticoagulants is disallowed within 12 hours unless being used for
   routine central venous line management, fibrinolytic instillation for central venous
   line occlusion, intermittent dialysis or ultrafiltration of CVVH.

   - Clinically significant uncontrolled acute bleeding, defined as hemorrhage requiring >
   15 cc/kg of packed red blood cells (e.g., a pediatric patient weighing 20 kg and
   requiring > 300cc of packed red blood cells/24 hours, or an adult patient weighing 70
   kg and requiring >3 units of packed red blood cells/24 hours) to replace blood loss,
   OR bleeding from a site which in the Investigator's opinion constitutes a potential
   life-threatening source (e.g. pulmonary hemorrhage or CNS bleeding), irrespective of
   amount of blood loss, at any point from the date of SCT through the date of severe VOD

   - Hemodynamic instability as defined by a requirement for multiple pressors, or
   inability to maintain mean arterial pressure (for children: to maintain mean arterial
   pressure within 1 standard deviation of age-adjusted levels) with single pressor

   - Woman who are pregnant.

Ages Eligible for Study

N/A - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Physician Referrals
Not Recruiting